Hers, Hims and Ozempic
Whoopi Goldberg had some trouble pronouncing WNBA star Diana Taurasi's name on Wednesday morning so, when the athlete herself ...
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
TD Cowen raised the firm’s price target on Hims & Hers to $44 from $28 and keeps a Buy rating on the shares. The firm continues to believe ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Hims & Hers faces new headwinds in its weight management segment with the Food and Drug Administration ending the shortage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback